Literature DB >> 11009218

The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.

H A Hanağasi1, G Kaptanoglu, H A Sahin, M Emre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11009218     DOI： 10.1002/1531-8257(200009)15:5<1016::aid-mds1042>3.0.co;2-j

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  5 in total

Review 1.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 2.  Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

Authors:  Albert Y Hung; Michael A Schwarzschild
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 3.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 4.  Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.

Authors:  Susan Duty
Journal:  CNS Drugs       Date:  2012-12       Impact factor: 5.749

5.  Treatment of advanced Parkinson's disease.

Authors:  Sara Varanese; Zoe Birnbaum; Roger Rossi; Alessandro Di Rocco
Journal:  Parkinsons Dis       Date:  2011-02-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.